327 related articles for article (PubMed ID: 35717838)
1. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.
Kalantari Y; Sadeghi S; Asadi D; Goodarzi A
Int Immunopharmacol; 2022 Sep; 110():108923. PubMed ID: 35717838
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
7. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
[TBL] [Abstract][Full Text] [Related]
8. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
[TBL] [Abstract][Full Text] [Related]
11. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
12. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
[TBL] [Abstract][Full Text] [Related]
14. Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis.
Juczynska K; Wozniacka A; Waszczykowska E; Danilewicz M; Wagrowska-Danilewicz M; Wieczfinska J; Pawliczak R; Zebrowska A
Mediators Inflamm; 2017; 2017():6716419. PubMed ID: 29203970
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
17. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
Karati D; Mahadik KR; Trivedi P; Kumar D
Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
20. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]